Search

Your search keyword '"Bruno V."' showing total 610 results

Search Constraints

Start Over You searched for: Author "Bruno V." Remove constraint Author: "Bruno V." Database Unpaywall Remove constraint Database: Unpaywall
610 results on '"Bruno V."'

Search Results

1. Complex Network Approaches for Epidemic Modeling: A Case Study of COVID-19

4. Novel Dihydropteridinone Derivatives As Potent Inhibitors of the Understudied Human Kinases Vaccinia-Related Kinase 1 and Casein Kinase 1δ/ε

7. AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication

11. Supplementary Table 1 from RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial

12. Supplementary Table 1 from RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial

13. Data from RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial

14. Data from RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial

15. Engineering a scalable and orthogonal platform for synthetic communication in mammalian cells

16. Sortable silt variations on the continental slope of Campos Basin (SW Atlantic): Implications of oceanographic processes

18. Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer

20. RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial

22. LRP1B—a prognostic marker in tubo-ovarian high-grade serous carcinoma

24. Bioética e Saúde Pública Volume 2

25. Bioética e Saúde Pública vol. 1

26. Teoria e Prática Multidisciplinar em Saúde - Volume 3

27. Teoria e Prática Multidisciplinar em Saúde - Volume 1

33. Prescriptive, descriptive or predictive models: what approach should be taken when empirical data is limited? Reply to comments on “Mathematical models for dengue fever epidemiology: A 10-year systematic review”

35. Figure S4 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial

36. Figure S1 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer

37. Supplementary Figure Legend from Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer

38. Figure S5 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial

39. Figure S2 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial

40. Figure S6 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial

41. Figure S3 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer

42. Table S1 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer

43. Table S2 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer

44. Supplementary Figure Legend from Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer

45. Figure S1 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial

46. Figure S7 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial

47. Figure S5 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial

48. Figure S8 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial

49. Figure S3 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer

50. Figure S2 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial

Catalog

Books, media, physical & digital resources